325 related articles for article (PubMed ID: 20519961)
21. Molecular differences in anticytokine therapies.
Calabrese LH
Clin Exp Rheumatol; 2003; 21(2):241-8. PubMed ID: 12747285
[TBL] [Abstract][Full Text] [Related]
22. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
23. Biological and clinical effects of anti-TNFalpha treatment.
Valesini G; Iannuccelli C; Marocchi E; Pascoli L; Scalzi V; Di Franco M
Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
[TBL] [Abstract][Full Text] [Related]
24. Effects of TNFalpha-antagonists on nitric oxide production in human cartilage.
Vuolteenaho K; Moilanen T; Hämäläinen M; Moilanen E
Osteoarthritis Cartilage; 2002 Apr; 10(4):327-32. PubMed ID: 11950256
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
26. Psoriatic arthritis: treatment strategies using biologic agents.
D'Angelo S; Palazzi C; Olivieri I
Reumatismo; 2012 Jun; 64(2):113-21. PubMed ID: 22690388
[TBL] [Abstract][Full Text] [Related]
27. [Biologic therapy with anti-TNFα in rheumathoid arthritis].
Ferraccioli G
Reumatismo; 2005; 57(4 Suppl):17-21. PubMed ID: 16385351
[TBL] [Abstract][Full Text] [Related]
28. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X;
Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor blockade: mechanism of action.
Gottlieb AB
J Investig Dermatol Symp Proc; 2007 May; 12(1):1-4. PubMed ID: 17502861
[TBL] [Abstract][Full Text] [Related]
30. Off-target activity of TNF-alpha inhibitors characterized by protein biochips.
Feyen O; Lueking A; Kowald A; Stephan C; Meyer HE; Göbel U; Niehues T
Anal Bioanal Chem; 2008 Jul; 391(5):1713-20. PubMed ID: 18344017
[TBL] [Abstract][Full Text] [Related]
31. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
[TBL] [Abstract][Full Text] [Related]
32. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
33. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
Wiedmann MW; Mössner J; Baerwald C; Pierer M
Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
[TBL] [Abstract][Full Text] [Related]
34. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
[TBL] [Abstract][Full Text] [Related]
35. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
[TBL] [Abstract][Full Text] [Related]
36. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.
Mitoma H; Horiuchi T; Hatta N; Tsukamoto H; Harashima S; Kikuchi Y; Otsuka J; Okamura S; Fujita S; Harada M
Gastroenterology; 2005 Feb; 128(2):376-92. PubMed ID: 15685549
[TBL] [Abstract][Full Text] [Related]
37. Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: a twelve-year "real life" experience.
Soubrier AS; Bele-Philippe P; Cortet B; Ramdane-Sebbane N; Bacle-Boutry MA; Lemeunier L; Flipo RM; Paccou J
Joint Bone Spine; 2015 Jan; 82(1):31-7. PubMed ID: 25311253
[TBL] [Abstract][Full Text] [Related]
38. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
Hirohata S
Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
[TBL] [Abstract][Full Text] [Related]
39. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
40. Binding and functional comparisons of two types of tumor necrosis factor antagonists.
Scallon B; Cai A; Solowski N; Rosenberg A; Song XY; Shealy D; Wagner C
J Pharmacol Exp Ther; 2002 May; 301(2):418-26. PubMed ID: 11961039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
